Aeglea Bio Therapeutics Inc (AGLE) Receives Average Recommendation of “Strong Buy” from Brokerages

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.

Brokerages have set a 1 year consensus price target of $24.00 for the company and are expecting that the company will post ($0.55) EPS for the current quarter, according to Zacks. Zacks has also given Aeglea Bio Therapeutics an industry rank of 196 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research raised Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $5.50 target price on the stock in a research note on Friday, November 10th.

Shares of Aeglea Bio Therapeutics (NASDAQ:AGLE) traded down $0.24 on Wednesday, hitting $6.03. The stock had a trading volume of 88,510 shares, compared to its average volume of 87,477. Aeglea Bio Therapeutics has a twelve month low of $2.81 and a twelve month high of $8.14. The firm has a market capitalization of $104.36, a price-to-earnings ratio of -3.45 and a beta of 2.99.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.07. Aeglea Bio Therapeutics had a negative return on equity of 44.05% and a negative net margin of 527.99%. The business had revenue of $1.26 million for the quarter. sell-side analysts expect that Aeglea Bio Therapeutics will post -1.97 EPS for the current fiscal year.

In other Aeglea Bio Therapeutics news, CEO Anthony G. Quinn purchased 8,288 shares of the company’s stock in a transaction dated Friday, December 8th. The shares were bought at an average price of $4.96 per share, with a total value of $41,108.48. Following the completion of the transaction, the chief executive officer now directly owns 32,009 shares in the company, valued at approximately $158,764.64. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Anthony G. Quinn purchased 7,956 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were acquired at an average cost of $4.98 per share, for a total transaction of $39,620.88. Following the transaction, the director now owns 14,100 shares of the company’s stock, valued at $70,218. The disclosure for this purchase can be found here. Insiders acquired 57,691 shares of company stock worth $269,483 in the last three months. Insiders own 27.00% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Aeglea Bio Therapeutics by 9.4% during the second quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock worth $579,000 after purchasing an additional 12,966 shares during the period. Susquehanna International Group LLP acquired a new stake in shares of Aeglea Bio Therapeutics during the second quarter worth about $653,000. Finally, Jennison Associates LLC raised its position in shares of Aeglea Bio Therapeutics by 0.6% during the fourth quarter. Jennison Associates LLC now owns 1,393,439 shares of the biotechnology company’s stock worth $7,539,000 after purchasing an additional 8,372 shares during the period. 46.98% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at

Aeglea Bio Therapeutics Company Profile

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Get a free copy of the Zacks research report on Aeglea Bio Therapeutics (AGLE)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply